SCIENION and Randox expand collaboration to transform high throughput biochip manufacturing

(PresseBox) ( Berlin, Germany / Crumlin, Northern Ireland, )

Multiyear alliance underpins Randox commitment to increase biochip manufacturing to transform rapid diagnostic testing
SCIENION AG to integrate its precision dispensing technology to enable Randox to scale-up Biochip manufacturing across the business
Joint activities will include co-working at Randox, Crumlin (Northern Ireland), Randox, Dungloe (Republic of Ireland), and at SCIENION AG headquarters in Berlin (Germany) – including massive scaling-up of SARS CoV2 test manufacturing

Randox today announced an important step in scaling-up biochip manufacturing by selecting SCIENION AG as its technology provider and science partner for this effort. The SCIENION engineering team has developed another full custom-made solution of the S100 in-line system to fulfill Randox’s manufacturing needs. SCIENION S100 manufacturing technology will significantly bolster Randox capabilities from research through commercialization and help accelerate the discovery and development of transformative diagnostics for patients worldwide.

Building on the well-established partnership between both companies, Randox and SCIENION have committed to immediately employ the new technology at manufacturing sites. This strategic alliance will focus on one core objective: to increase Randox manufacturing capacity for biochips significantly and immediately.

SCIENION and Randox will also collaborate to develop and apply next-generation diagnostics platforms and processes that support future key programs. The overall investment will include project funding, subject-matter experts, technology, and tools.

Mr John Lamont – Director of R&D at Randox Laboratories, said, “As Randox continues evolving into a focused diagnostics company powered by advanced multiplexed tests and data science, alliances like this will help us deliver on our goal to improve healthcare worldwide. Pairing our deep understanding of diagnostics with SCIENION’s leading expertise in high throughput microarray manufacturing, this could transform the way we discover and develop diagnostic tests for the world.”

SCIENION UK Ltd Managing Director, Dr. Andrew Sweet, added, “Our strategic alliance will combine Randox Diagnostics expertise with the power of SCIENION precision liquid handling and sciFLEXARRAYER S100 technology. Together, we aim to address some of the biggest challenges facing the life sciences industry today. This would quickly bring reliable rapid diagnostic testing technology to the frontline for widespread use in all affected regions during a pandemic such as SARS-CoV2.

For more information or to arrange interviews, please contact either or

About Randox

Randox is a global leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis using Randox products each year. Randox is the largest diagnostic company from the UK and exports over 95% of products worldwide. Our products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories.

With more than 1500 employees of 44 nationalities, including 430 research scientists and engineers, we have offices and distribution in over 145 countries. There are four key manufacturing and research and development sites, located in County Antrim, Northern Ireland; Dungloe, County Donegal, Ireland; Bangalore, India; and one in development in the Greater Washington DC area, USA. Our Randox Health Clinics are currently located in London and Belfast, with ambitious plans to roll out a number of new clinics in the coming months and years. A mobile service enabling certified Randox Health staff to visit clients at their convenience has also been launched.

With a major focus in R&D, Randox scientists work in pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease. With around 25% of turnover reinvested in R&D, Randox has more new tests in development than any other diagnostic company.

Our scientists have spent over £305 million researching the thousands of biomarkers present in our bodies and have identified the gold standard in testing. Our patented Biochip Array Technology is the world’s only diagnostic grade biochip. This state-of-the-art technology has revolutionised the diagnostics industry by offering a unique testing platform which allows multiple tests to be carried out from a single patient sample at our Randox Health Clinics.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an